Tridek-One is a biopharmaceutical company aiming to develop immunomodulatory compounds targeting the CD31 pathway.
Tridek is a developer of immunomodulatory products intended for moderating overactive responses without blockade. The company's product is a peptide which maintains cluster of truncated CD31 to the membrane for a diversity of auto-immune and inflammatory disorders, enabling medical companies to treat their patients with better drugs and give them a better life.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 15, 2022 | Series Unknown | €16M | 5 | Pureos Bioventures | — | Detail |
Jun 4, 2019 | Series Unknown | €3M | 2 | AdBio partners | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Pureos Bioventures | Yes | Series Unknown |
AdBio partners | — | Series Unknown |
Advent Life Sciences | — | Series Unknown |
Bioqube Ventures | — | Series Unknown |
Bpifrance | — | Series Unknown |